Dermovayt - instructions for use, reviews, analogs and forms of release (ointment 0.05%, cream or gel) of hormonal medication for the treatment of psoriasis, eczema, dermatitis in adults, children and pregnancy. Composition

In this article you can get acquainted with the instructions for the use of a hormonal drug Dermovayt. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Dermovayt in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Dermoveit with available structural analogues. Use for the treatment of psoriasis, eczema, dermatitis in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Dermovayt - Glucocorticosteroid (GCS) for external use.It prevents the accumulation of neutrophils, reduces inflammatory exudation and production of lymphokines, inhibits the migration of macrophages, reduces the intensity of infiltration and granulation processes, exerts local anti-inflammatory, antipruritic, anti-allergic antiexudative effects.

Composition

Clobetasol propionate + auxiliary substances.

Pharmacokinetics

External GCS can be systemically absorbed from intact healthy skin. The degree of percutaneous absorption of GCS for external use is determined by a number of factors, including the basis of the drug and the integrity of the epidermal barrier. Occlusion, inflammation and / or other pathological process on the skin side are also capable of increasing percutaneous absorption. After absorption through the skin, GCS for external use is metabolized by the same pharmacokinetic pathways as the GCS for systemic use. They are metabolized, mainly, in the liver.

Indications

Dermoveit is a highly active SCS for external use, which is indicated for use in adults,elderly people and children over the age of 1 year to alleviate the symptoms of inflammation and skin pruritus with dermatoses sensitive to GCS therapy:

psoriasis (excluding common plaque psoriasis);
eczema (various forms);
red flat lichen;
discoid lupus erythematosus;
Dermatoses resistant to therapy with less active GCS for external use.

As the preparation in the form of an ointment promotes preservation of a moisture in a skin it is recommended to apply ointment for external application Dermovajt at lesions of a skin, accompanied by its dryness, a hyperkeratosis and a thickening.

Forms of release

Ointment for external use 0.05% (sometimes mistakenly called a gel).

Cream for external use.

Instructions for use and how to use them

Ointment

Outwardly.

The ointment is applied in a thin layer in an amount sufficient to cover the entire affected area, 1-2 times a day, gently rubbed. Duration of application - before the appearance of the effect or, if necessary, up to 4 weeks. If you want to continue treatment, it is recommended to gradually reduce the frequency of application or switch to the use of a less active drug.Ensure that there is sufficient time to act after each application of Dermovate before applying the emollient. For treatment of exacerbations of skin diseases, repeat courses are carried out with the drug Dermoveit.

In especially resistant cases, especially in the presence of hyperkeratosis, the effect of ointment for external use of Dermovayt can be enhanced by overlapping the area of application of the occlusive dressing for the night, which is usually accompanied by a positive effect. In the future, the achieved effect can be maintained without the use of an occlusive dressing.

If the condition worsens or does not improve within 2-4 weeks, the diagnosis and treatment should be reviewed.

The maximum weekly dose should not exceed 50 g per week.

Atopic dermatitis (eczema)

Treatment with clobetasol should be gradually withdrawn immediately after the control of the disease is achieved, and treatment with an emollient should be continued as maintenance therapy.

A sudden withdrawal of clobetasol can lead to a recurrence of previously existing dermatosis.

Eczema (various forms)

Patients with frequent relapses of the disease

In case of acute disease, once the effect of a continuous course of external glucocorticosteroid treatment is achieved, the possibility of its intermittent use (once a day, twice a week, without an occlusive dressing) can be considered. It is shown that such treatment effectively reduces the frequency of relapse.

Application of the drug should be continued on all previously affected areas of the skin or to known areas of potential exacerbation. Such a scheme of application should be combined with routine daily application of emollients. A regular assessment of the condition, as well as the benefits and risks of continuing treatment, should be carried out.

Special patient groups

Children

Children are more likely to develop local and systemic side effects with external glucocorticosteroid therapy and generally require shorter courses of treatment with less active agents than adults.

Care should be taken when using clobetasol in children to ensure that it is applied in a minimal amount that provides a therapeutic effect.

Elderly patients

Clinical studies have not revealed any differences in the effectiveness of the drug in the elderly and younger patients. The high prevalence of decreased hepatic or renal function in elderly patients can lead to a delay in the excretion of the drug if it is systemically absorbed. Therefore, it should be used in elderly patients in minimal amounts and for as short a period as possible, while ensuring the achievement of the necessary clinical effect.

Patients with impaired renal and / or liver function

In the case of systemic absorption of the drug (when applied to large areas of the skin for an extended period), its metabolism and excretion may slow down, leading to an increased risk of developing systemic toxicity. Therefore, it should be used in such patients in minimal amounts and for as short a period as possible, while ensuring the achievement of the necessary clinical effect.

Cream

Outwardly.

The application of the cream is particularly suitable for wet or wet surfaces.

The cream is applied in a thin layer in an amount sufficient to cover the entire affected area,1-2 times a day, gently rubbed. Duration of application - before the appearance of the effect or, if necessary, up to 4 weeks. If you want to continue treatment, it is recommended to gradually reduce the frequency of application or switch to using a less active drug. Ensure that there is sufficient time to act after each application of Dermovate before applying the emollient. For treatment of exacerbations of skin diseases, repeat courses are carried out with the drug Dermoveit.

In particularly resistant cases, especially in the presence of hyperkeratosis, the effect of the cream for external use of Dermovayt can be enhanced by overlapping the area of application of the occlusive dressing for the night, which is usually accompanied by a positive effect. In the future, the achieved effect can be maintained without the use of an occlusive dressing.

If the condition worsens or does not improve within 2-4 weeks, the diagnosis and treatment should be reviewed.

The maximum weekly dose should not exceed 50 g per week.

Atopic dermatitis (eczema)

Treatment with clobetasol should be gradually eliminated immediately after achieving control of the disease,and treatment with an emollient should be continued as maintenance therapy.

A sudden withdrawal of clobetasol can lead to a recurrence of previously existing dermatosis.

Eczema (various forms)

Patients with frequent relapses of the disease

In the case of acute disease, once the effect of a continuous course of external treatment for GCS has been achieved, the possibility of its intermittent use (once a day, 2 times a week, without an occlusive dressing) can be considered. It is shown that such treatment effectively reduces the frequency of relapse.

Side effect

infection caused by opportunistic organisms;
hypersensitivity;
oppression of the hypothalamic-pituitary-adrenal system;
signs of the Cushingoid (moon face, obesity by the central type);
delay in weight gain and / or growth retardation in children;
osteoporosis;
glaucoma;
hyperglycemia and / or glucosuria;
cataract;
hypertension;
weight gain or obesity;
decrease in the level of endogenous cortisol;
alopecia;
brittle hair;
itching;
feeling of burning or soreness;
local skin atrophy;
stria;
telangiectasia;
thinning, wrinkling of the skin;
dry skin;
hypertrichosis;
aggravation of the symptoms of the disease;
allergic contact dermatitis;
pustular psoriasis;
erythema;
rash;
hives;
irritation and / or soreness in the application site.

When applied to large surfaces for a long period of time (for example, more than 2 weeks), the systemic side effects may develop in patients: gastritis, ulceration of the gastrointestinal mucosa, increased intraocular pressure, symptoms of hypercorticism.

Contraindications

bacterial, viral and fungal skin diseases (including herpes simplex, chicken pox, skin tuberculosis, actinomycosis);
pink acne (rosacea);
acne;
skin cancer;
nodular pruritus of Gaida;
perioral dermatitis;
itching in the absence of inflammation;
perianal and genital itching;
common plaque psoriasis;
age up to 1 year (including infants and newborns);
lactation period;
hypersensitivity to the active ingredient and auxiliary components of the drug.

Caution should be used during pregnancy.

Application in pregnancy and lactation

Dermovayt should not be used during pregnancy in large doses for a long time. In studies it was not found that the use of the drug during pregnancy has a negative effect on the health of a woman or a fetus.

The drug should be used during pregnancy only if the potential benefit to the mother exceeds the potential risk to the fetus.

Dermovate during the lactation period is contraindicated.

Use in children

It should avoid the appointment of GCS for external use for a long time, especially in the treatment of young children, tk. while the functions of the adrenal glands may be suppressed. The use of Dermoveit in children requires observation at the doctor at least once a week. On the face more often than in other parts of the body, as a result of prolonged use of local SCS, atrophic changes in the skin can appear,which must be taken into account in the treatment of psoriasis, discoid lupus erythematosus and severe eczema with localization of rashes on the face.

Children are more likely to develop local and systemic side effects with external glucocorticosteroid therapy and generally require shorter courses of treatment with less active agents than adults.

Caution should be exercised when using Dermovain in children to ensure that it is applied in a minimal amount that provides a therapeutic effect.

Contraindicated in children under 1 year.

Application in elderly patients

Clinical studies have not revealed any difference in the effectiveness of Dermovate in elderly and younger patients. The high prevalence of decreased hepatic or renal function in elderly patients can lead to a delay in the excretion of the drug if it is systemically absorbed. Therefore, it should be used in elderly patients in minimal amounts and for as short a period as possible, while ensuring the achievement of the necessary clinical effect.

special instructions

Dermoveit should be used with caution in patients with a history of local hypersensitivity to glucocorticosteroids or to any of the excipients in the formulation. Local hypersensitivity reactions may be similar to the symptoms of a current disease. In some individuals, as a result of increased systemic absorption of GCS for external use, hypercorticism (Cushing's syndrome) and reversible oppression of the hypothalamic-pituitary-adrenal system leading to glucocorticosteroid insufficiency may occur. If any of the above is observed, it is necessary to cancel the drug, gradually reducing the frequency of its application, or replace it with a less active GCS. A sudden cessation of treatment can lead to the development of glucocorticosteroid insufficiency.

The risk factors for enhancing systemic effects include the following: activity and dosage form of GCS for external use, duration of application, application of the drug to large areas of the skin, application in closed areas of the skin (ie, in intertriginous zones or under occlusive dressings (diapers and diapers Infants can play a roleocclusive dressing), increased hydration of the stratum corneum, use on areas with thin skin such as face, application to damaged skin or other conditions that may be accompanied by a violation of the integrity of the skin barrier. Compared to adults, children and infants may have a greater percentage of absorbing GCS for external use, and this category of patients is more at risk of developing systemic side effects. This is due to the fact that children have an immature skin barrier and a greater value of the ratio of body surface area to body weight compared to adults.

Use in psoriasis

Treatment of psoriasis with Dermovay may be accompanied by the resumption of symptoms of the disease, drug resistance, the development of generalized pustular psoriasis and local or systemic adverse reactions due to disruption of skin barrier function, so careful monitoring of the patient is especially important.

Concomitant Infection

When attaching a secondary infection, appropriate antibiotic therapy should be carried out.With any signs of generalization of the infection, it is necessary to stop the external application of GCS and to conduct appropriate treatment with antibacterial drugs.

Risk of infection with occlusion

Warm moist conditions created with the application of occlusive dressing, contribute to the emergence of a bacterial infection, so you should always carefully clean the skin before applying a new bandage with the drug Dermovayt.

Chronic ulcers of the shins

External glucocorticosteroids are sometimes used to treat dermatitis around chronic ulcers of the shins. However, such use may be accompanied by an increased incidence of local hypersensitivity reactions and an increased risk of developing local infections.

Application on the face skin

Application to the skin is undesirable, because This area is more susceptible to the development of atrophic changes. In case of application to the skin of the face, treatment should be limited to a few days.

Application on the eyelids

When applying the cream on the eyelids, care should be taken to ensure that the product does not get into the eyes, because repeated exposure to the cream can cause cataracts and glaucoma.

Impact on the ability to drive vehicles and manage mechanisms

Studies to study the effect of clobetasol on the ability to drive vehicles or work with mechanisms have not been conducted. Based on the profile of adverse reactions of clobetasol for external use, no adverse effect on such activities is expected.

Drug Interactions

It has been shown that simultaneous use of drugs capable of inhibiting the isoenzyme CYP3A4 (eg, ritonavir and itraconazole) inhibits the metabolism of GCS, leading to an increase in their systemic exposure. The degree of clinical significance of this interaction depends on the dose and method of application of GCS and the activity of the inhibitor of the isoenzyme CYP3A4.

Analogues of the drug Dermovayt

Structural analogs for the active substance:

Cloveit;
Powercort;
Etreex.

Analogues on the curative effect (agents for the treatment of psoriasis):

Azathioprine;
Acriderm;
Allopurinol;
Arthromax;
Afloderm;
Belogent;
Beloderm;
Belosalik;
Betaderm;
Betnoveit;
Befungin;
Let's see;
Hydrocortisone;
Decortin;
Diprosalic;
Diprosalik lotion;
Diprospan;
Imunofan;
Ichthyol ointment;
Calcium gluconate;
Kenakorth;
Kenalog;
Kutiweit;
Latticort;
Lycopid;
Lokoid;
Loma Psoriasis;
Lorinden;
Methotrexate;
Momat;
Oksoralen;
Pyridoxine;
Polcortolone;
Psoriathen;
Psoriser;
Psorkutan;
Radevit;
Ribasan forte;
Sinaflan;
Skin cap;
Thiamine chloride;
Triamsinolone;
Fenkarol;
Flukort;
Flucinar;
Phosphogliv Forte;
Fluorocort;
Celestoderm B;
Celeston;
Cyclosporin;
Эветрекс;
Elokom;
Eslidine;
Essentiale;
Essliver forte.

If there are no analogues of the medication for the active substance, you can go to the links below for diseases, from which the corresponding drug helps, and to look at the available analogs for therapeutic effects.

Used for the treatment of diseases: psoriasis, eczema, dermatitis, lichen, discoid lupus erythematosus, neurodermatitis, contact dermatitis, allergic dermatitis, lichen planus, chronic lichen